Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

RCC incidence rates stabilize while mortality rates drop

Saad AM et al. Clin Genitourin Cancer. 2018. doi: 10.1016/j.clgc.2018.10.002.

Key clinical point: In recent years, renal cell carcinoma incidence rates have stabilized, while mortality due to the disease has dropped sharply.

Major finding: Mortality rates increased from 1992 and peaked in 2001, at which point they started to drop at an ever accelerating pace, culminating in an annual percent decrease of 32.2% in the 2013-2015 time period.

Study details: Analysis including more than 104,000 patients with an RCC diagnosis in the Surveillance, Epidemiology and End Results (SEER) database from 1992 to 2015.

Disclosures: Support for the study came from the National Cancer Institute and the Department of Defense. Study authors declared that they had no conflicts of interest.

Read the article.

Citation:

Saad AM et al. Clin Genitourin Cancer. 2018. doi: 10.1016/j.clgc.2018.10.002.